Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?

Detalles Bibliográficos
Autores principales: Garraud, Olivier, Watier, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Clinical Trial Section (Editorial)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164650/
https://www.ncbi.nlm.nih.gov/pubmed/37169698
http://dx.doi.org/10.1016/j.transci.2023.103726
_version_ 1785038110887772160
author Garraud, Olivier
Watier, Hervé
author_facet Garraud, Olivier
Watier, Hervé
author_sort Garraud, Olivier
collection PubMed
description
format Online
Article
Text
id pubmed-10164650
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101646502023-05-08 Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans? Garraud, Olivier Watier, Hervé Transfus Apher Sci Clinical Trial Section (Editorial) Elsevier Ltd. 2023-06 2023-05-08 /pmc/articles/PMC10164650/ /pubmed/37169698 http://dx.doi.org/10.1016/j.transci.2023.103726 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Trial Section (Editorial)
Garraud, Olivier
Watier, Hervé
Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title_full Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title_fullStr Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title_full_unstemmed Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title_short Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
title_sort is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat sars-cov-2 variants and are we rethinking preparedness plans?
topic Clinical Trial Section (Editorial)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164650/
https://www.ncbi.nlm.nih.gov/pubmed/37169698
http://dx.doi.org/10.1016/j.transci.2023.103726
work_keys_str_mv AT garraudolivier isthereanyrevivaloftheuseofplasmatherapyorneutralizingconvalescentantibodytherapytotreatsarscov2variantsandarewerethinkingpreparednessplans
AT watierherve isthereanyrevivaloftheuseofplasmatherapyorneutralizingconvalescentantibodytherapytotreatsarscov2variantsandarewerethinkingpreparednessplans

Ejemplares similares